EMG
CCXI

Ellington Management Group’s ChemoCentryx, Inc. CCXI Stock Holding History

Ellington Management Group’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-25,200
Closed -$343K – 943
2018
Q1 		$343K Buy
+25,200
New +$260K 0.02% 537

Other funds holding CCXI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Ellington Management Group's CCXI Position: Q2 2018 in Review

Ellington Management Group sold out of ChemoCentryx, Inc. (CCXI) in Q2 2018, closing a stake of 25,200 shares — an estimated $343K sold.

Ellington Management Group first reported a position in CCXI in Q1 2018 and held it in 1 quarter. The position peaked at $343K in Q1 2018. 115 funds tracked by Wall St. Rank hold CCXI as of Q2 2018.

  • Ellington Management Group reported no remaining ChemoCentryx, Inc. position as of Q2 2018 after selling out during the quarter.
  • Ellington Management Group sold 25,200 ChemoCentryx, Inc. shares in Q2 2018, an estimated $343K.
  • Ellington Management Group first reported a position in ChemoCentryx, Inc. in Q1 2018 and held it in 1 quarter.
  • Ellington Management Group's ChemoCentryx, Inc. position peaked at $343K in Q1 2018.
  • 115 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2018.

Based on Ellington Management Group's 13F filing for Q2 2018, filed 14 Aug 2018.